Objectives
The primary objective was to determine the effects of a policy of 'use acupuncture', compared with a policy of 'avoid acupuncture', on headache in primary care patients with chronic headache disorders. Secondary objectives were to determine the effects of using acupuncture compared with avoiding acupuncture on medication use, quality of life, resource use and days off sick in this population and to determine the cost-effectiveness of acupuncture.
Methods Design
This study was conducted as a randomised, controlled trial.
Setting
General practices in England and Wales.
Participants
The study included 401 patients with chronic headache disorder, predominantly migraine.
Interventions
Patients were randomly allocated to receive up to 12 acupuncture treatments over 3 months or to a control intervention offering usual care.
Main outcome measures
The outcome measures included headache score, assessment of Short Form 36 (SF-36) health status and use of medication at baseline, 3 months and 12 months; use of resources was assessed every 3 months; and assessment of incremental cost per quality-adjusted life-year (QALY) gained for the purposes of economic evaluation.
Results
Headache score at 12 months, the primary endpoint, was lower in the acupuncture group (mean 16.2, SD 13.7, n = 161, 34% reduction from baseline) than in controls (22.3, SD 17.0, n = 140, 16% reduction from baseline). The adjusted difference between means was 4.6 (95% confidence interval 2.2 to 7.0, p = 0.0002). This result is robust to sensitivity analysis incorporating imputation for missing data. Patients in the acupuncture group experienced the equivalent of 22 fewer days of headache per year (8 to 38). SF-36 data favoured acupuncture, although differences reached significance only for physical role functioning, energy and change in health. Compared with controls, patients randomised to acupuncture used 15% less medication (p = 0.02), made 25% fewer visits to GPs (p = 0.10) and took 15% fewer days off sick (p = 0.2). Total costs during the 1-year period of the study were on average higher for the acupuncture group (£403, $768, €598) than for controls (£217) because of the acupuncture practitioners' costs. The mean health gain from acupuncture during the year of the trial was 0.021 QALYs, leading to a base-case estimate of £9180 per QALY gained. This result was robust to sensitivity analysis. Cost per QALY dropped substantially when the analysis incorporated likely QALY differences for the years after the trial.
Conclusions Implications for healthcare
The results of the study suggest that acupuncture leads to persisting, clinically relevant benefits for primary care patients with chronic headache, particularly migraine. It is relatively cost-effective compared with a number of other interventions provided by the NHS.
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Implications for research
The optimal methods of acupuncture remain unknown and require systematic research. Further studies could examine the duration of acupuncture effects beyond 1 year and the relative benefit to patients with migraine compared with tension-type headache. Trials are also warranted examining the effectiveness and cost-effectiveness of acupuncture in patients with headache receiving more aggressive pharmacological management. NHS R&D HTA Programme T he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.
Publication
The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.
The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, consumer groups and professional bodies such as Royal Colleges and NHS Trusts.
Research suggestions are carefully considered by panels of independent experts (including consumers) whose advice results in a ranked list of recommended research priorities. The HTA Programme then commissions the research team best suited to undertake the work, in the manner most appropriate to find the relevant answers. Some projects may take only months, others need several years to answer the research questions adequately. They may involve synthesising existing evidence or designing a trial to produce new evidence where none currently exists.
Additionally, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme is able to commission bespoke reports, principally for NICE, but also for other policy customers, such as a National Clinical Director. TARs bring together evidence on key aspects of the use of specific technologies and usually have to be completed within a limited time period.
The research reported in this monograph was commissioned by the HTA Programme as project number 96/40/15. As funder, by devising a commissioning brief, the HTA Programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
